| Literature DB >> 33005692 |
Laura E Carreto-Binaghi1, Esmeralda Juárez1, Silvia Guzmán-Beltrán1, María Teresa Herrera1, Martha Torres1, Alejandro Alejandre2, José Arturo Martínez-Orozco3, Eduardo Becerril-Vargas3, Yolanda Gonzalez1.
Abstract
Childhood tuberculosis (TB) is a significant public health problem and the ninth leading cause of death worldwide. Progression of Mycobacterium tuberculosis infection to active disease depends on mycobacterial virulence, environmental diversity, and host susceptibility and immune response. In children, malnutrition and immaturity of the immune system contribute to an inadequate immune response. Coinfections, though rarely described in TB, might be associated with host immune deficiencies. Here, we describe the immunological evaluation of eight pediatric patients infected with a member of the M. tuberculosis complex, most of them with concomitant pulmonary infections (bacteria, viruses, or fungi). We assessed the functionality of several innate immunity receptors, IL-12 receptor, and IFN-γ receptor, as well as the antioxidant levels (glutathione), which are essential mechanisms for fighting intracellular pathogens such as M. tuberculosis. This study is aimed at developing a thorough immunological evaluation of patients with TB and a coinfection.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33005692 PMCID: PMC7509549 DOI: 10.1155/2020/8235149
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Figure 1Strategy to assess the functionality of innate and adaptive immunity. (a) Innate receptors TLR2, TLR4, TLR9, NOD1, and NOD2 were stimulated with their synthetic ligands for the production of IL-8. IFN-γ receptor was stimulated with rhIFN-γ for the production of TNF-α. (b) IL-12 receptor was stimulated with rhIL-12 for the production of IFN-γ. (c) The cellular risk for oxidative damage was determined by measuring the extracellular reduced glutathione (GSH) in plasma.
Clinical and demographical data of TB patients.
| Subjects | Age | Sex | BMI (kg/m2) | TB type | Concomitant infections | TB treatment | Treatment duration |
|---|---|---|---|---|---|---|---|
| Patient 1 | 14 | F | 15.2 | Pulmonary | Unknown fungus | HRZE | 18 months |
| Patient 2 | 5 | M | 13.6 | Pulmonary |
| HRZE | 6 months |
| Patient 3 | 12 | F | 19.3 | Lymph node | No | HRZE | 2 years |
| Patient 4 | 16 | F | 18.5 | Bone | No | HRZE | 2 years |
| Patient 5 | 13 | F | 20.3 | Lymph node (RR) | No | H, Lfx, Dlm, Lzd, Cfz | 18 months |
| Patient 6 | 1 | F | 14.7 | Pulmonary | Rhinovirus | HRZE | 6 months |
| Patient 7 | 1 | F | 11.5 | Pulmonary | Flu A H1N1 | HRZE | 6 months |
|
| |||||||
| Patient 8 | 4 | F | 13.2 | Pulmonary |
| HRZE | 6 months |
TB: tuberculosis; RR: rifampin resistant; H: isoniazid; R: rifampin; Z: pyrazinamide; E: ethambutol; Lfx: levofloxacin; Dlm: delamanid; Lzd: linezolid; Cfz: clofazimine.
Innate (NLR/TLR and IFN-γ receptors) responses, antioxidant levels, and adaptive IL-12 receptor responses elicited within the study group.
| Stimulated receptor | NOD1a | NOD2a | TLR2a | TLR4a | TLR9a | Antioxidant levelsb | IFN- | IL-12 receptord | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subject | TriDAP | MDP | Pam-3-cys | LPS | CpG | Type of response | GSH (nmol/mg protein) | Type of response | LPS | LPS+rhIFN- | LPS+rhIFN- | LPS+rhIFN- | Type of response | rhIL-12 | PHA | rhIL-12+PHA | Type of response |
| Patient 1 | 296 | 990 | 25480 | 26090 | 126 | Low NLR | 0.5 | Low | 364 | 4391 | 4041 | 7841 | Adequate | 11 | 2461 | 3029 | Low |
| Patient 2 | 891 | 2393 | 24672 | 55372 | 208 | Adequate | 1.6 | Adequate | nd | nd | nd | nd | nd | 0 | 23793 | 65315 | High |
| Patient 3 | 1142 | 10393 | 48171 | 31838 | 0 | Adequate | 1.2 | Adequate | 2071 | 3989 | 4013 | 2460 | Adequate | 0 | 469 | 12597 | Low |
| Patient 4 | 0 | 1153 | 28253 | 24187 | 0 | Low NLR | 1.7 | Adequate | 845 | 3181 | 9738 | 8647 | Adequate | 0 | 4619 | 15450 | Low |
| Patient 5 | 2109 | 10293 | 54982 | 45682 | 382 | Adequate | 2.1 | Adequate | 2146 | 2744 | 1618 | 3228 | Adequate | 10 | 13172 | 25972 | Adequate |
| Patient 6 | 0 | 32166 | 59726 | 38926 | 0 | Adequate | 1.3 | Adequate | 1905 | 567 | 1861 | 1099 | Adequate | 2 | 7754 | 20511 | Low |
| Patient 7 | 21680 | 30780 | 114900 | 52480 | 1690 | High | 1.6 | Adequate | 144 | 187 | 206 | 285 | Low | 5 | 248 | 1677 | Low |
| Patient 8 | 0 | 2917 | 90728 | 72478 | 0 | Adequate | 1.4 | Adequate | 1826 | 348 | 0.2 | 0 | Low | nd | nd | nd | |
| Healthy donors ( | 803 [160.7, 1967] | 5158 [1210, 23050] | 49189 [23306, 74664] | 45903 [25933, 92485] | 163.3 [0.0, 789.2] | Reference value | 1.575 [1.160, 1.760] | Reference value | 2365 [197.3, 7403] | 5924 [861.5, 12150] | 7754 [529.9, 10925] | 9017 [844.9, 11557] | Reference value | 17.37 [0.0, 78.34] | 17036 [9337, 25752] | 34088 [27614, 58018] | Reference value |
aReadout IL-8 production, pg/ml. NLR and TLR response was defined as low or high: outside LL or UL values of the 99% CI in the healthy volunteers. bLow antioxidant levels: value below to LL with a 99% CI in the healthy volunteers. cReadout TNF-α production, pg/ml. Low or high response of IFNGR was defined as TNF-α concentration outside LL or UL value of the 99% CI in the healthy volunteers. The IFNGR receptor increases <100% of the TNF-α concentration after LPS+rhIFN-γ vs. LPS alone. dReadout IFN-γ production, pg/ml. Low or high response of IL-12R was defined as IFN-γ concentration outside LL or UL values of the 99% CI in the healthy volunteers. The IL-12 increases <100% of the IFN-γ production after rhIL-12 plus PHA stimulation with respect to PHA alone. CI: confidence interval; LL: lower limit; UL: upper limit; nd: not determined.
Figure 2Graphical expression of the results of the immunological evaluation. As an aid in the interpretation of results, the graphical comparison of innate (a, b) and adaptive (c, d) responses between patient one and the mean of the control group is depicted.